S&P 500   4,068.46 (-0.29%)
DOW   34,272.75 (-0.92%)
QQQ   293.13 (-0.08%)
AAPL   147.86 (-0.11%)
MSFT   252.94 (-0.86%)
META   119.71 (+1.36%)
GOOGL   101.23 (+0.24%)
AMZN   96.34 (-0.21%)
TSLA   195.44 (+0.38%)
NVDA   170.59 (+0.80%)
NIO   12.36 (-3.29%)
BABA   86.24 (-1.51%)
AMD   77.29 (-0.44%)
T   19.22 (-0.31%)
MU   56.26 (-2.41%)
CGC   3.70 (+2.21%)
F   14.12 (+1.58%)
GE   85.41 (-0.65%)
DIS   98.31 (+0.45%)
AMC   8.39 (+16.04%)
PYPL   78.72 (+0.40%)
PFE   50.55 (+0.84%)
NFLX   315.96 (+3.41%)
S&P 500   4,068.46 (-0.29%)
DOW   34,272.75 (-0.92%)
QQQ   293.13 (-0.08%)
AAPL   147.86 (-0.11%)
MSFT   252.94 (-0.86%)
META   119.71 (+1.36%)
GOOGL   101.23 (+0.24%)
AMZN   96.34 (-0.21%)
TSLA   195.44 (+0.38%)
NVDA   170.59 (+0.80%)
NIO   12.36 (-3.29%)
BABA   86.24 (-1.51%)
AMD   77.29 (-0.44%)
T   19.22 (-0.31%)
MU   56.26 (-2.41%)
CGC   3.70 (+2.21%)
F   14.12 (+1.58%)
GE   85.41 (-0.65%)
DIS   98.31 (+0.45%)
AMC   8.39 (+16.04%)
PYPL   78.72 (+0.40%)
PFE   50.55 (+0.84%)
NFLX   315.96 (+3.41%)
S&P 500   4,068.46 (-0.29%)
DOW   34,272.75 (-0.92%)
QQQ   293.13 (-0.08%)
AAPL   147.86 (-0.11%)
MSFT   252.94 (-0.86%)
META   119.71 (+1.36%)
GOOGL   101.23 (+0.24%)
AMZN   96.34 (-0.21%)
TSLA   195.44 (+0.38%)
NVDA   170.59 (+0.80%)
NIO   12.36 (-3.29%)
BABA   86.24 (-1.51%)
AMD   77.29 (-0.44%)
T   19.22 (-0.31%)
MU   56.26 (-2.41%)
CGC   3.70 (+2.21%)
F   14.12 (+1.58%)
GE   85.41 (-0.65%)
DIS   98.31 (+0.45%)
AMC   8.39 (+16.04%)
PYPL   78.72 (+0.40%)
PFE   50.55 (+0.84%)
NFLX   315.96 (+3.41%)
S&P 500   4,068.46 (-0.29%)
DOW   34,272.75 (-0.92%)
QQQ   293.13 (-0.08%)
AAPL   147.86 (-0.11%)
MSFT   252.94 (-0.86%)
META   119.71 (+1.36%)
GOOGL   101.23 (+0.24%)
AMZN   96.34 (-0.21%)
TSLA   195.44 (+0.38%)
NVDA   170.59 (+0.80%)
NIO   12.36 (-3.29%)
BABA   86.24 (-1.51%)
AMD   77.29 (-0.44%)
T   19.22 (-0.31%)
MU   56.26 (-2.41%)
CGC   3.70 (+2.21%)
F   14.12 (+1.58%)
GE   85.41 (-0.65%)
DIS   98.31 (+0.45%)
AMC   8.39 (+16.04%)
PYPL   78.72 (+0.40%)
PFE   50.55 (+0.84%)
NFLX   315.96 (+3.41%)
NASDAQ:ATRC

AtriCure - ATRC Stock Forecast, Price & News

$45.90
+0.34 (+0.75%)
(As of 12/1/2022 11:12 AM ET)
Add
Compare
Today's Range
$45.49
$46.07
50-Day Range
$33.48
$47.45
52-Week Range
$32.51
$74.85
Volume
726 shs
Average Volume
260,793 shs
Market Capitalization
$2.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.17

AtriCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.1% Upside
$60.17 Price Target
Short Interest
Bearish
2.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of AtriCure in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$229,168 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.10) to ($0.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

691st out of 1,047 stocks

Surgical & Medical Instruments Industry

75th out of 104 stocks

ATRC stock logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Lowered to "Sell" at StockNews.com
AtriCure Reports Third Quarter 2022 Financial Results
AtriCure to Announce Third Quarter 2022 Financial Results
Oversold Conditions For AtriCure (ATRC) - Nasdaq
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings
11/03/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/21/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
875
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$60.17
High Stock Price Forecast
$71.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+31.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$50.20 million
Pretax Margin
-17.69%

Debt

Sales & Book Value

Annual Sales
$274.33 million
Cash Flow
$1.00 per share
Book Value
$9.68 per share

Miscellaneous

Free Float
45,206,000
Market Cap
$2.13 billion
Optionable
Optionable
Beta
1.23

Social Links


Key Executives

  • Mr. Michael H. Carrel (Age 51)
    CEO, Pres & Director
    Comp: $1.94M
  • Ms. Angela L. Wirick CPAMs. Angela L. Wirick CPA (Age 44)
    Chief Financial Officer
    Comp: $694.64k
  • Mr. Douglas J. SeithMr. Douglas J. Seith (Age 56)
    Chief Operating Officer
    Comp: $1.17M
  • Dr. Vinayak Doraiswamy Ph.D.Dr. Vinayak Doraiswamy Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $777.66k
  • Mr. Justin J. NozneskyMr. Justin J. Noznesky (Age 44)
    Chief Marketing & Strategy Officer
    Comp: $700.74k
  • Mr. Salvatore Privitera J.D.Mr. Salvatore Privitera J.D. (Age 55)
    Chief Technical Officer
  • Mr. Karl S. Dahlquist C.C.E.P. (Age 52)
    CCEP, J.D., Chief Legal & Compliance Officer
  • Valerie Storch-Willhaus
    VP of Corp. Marketing & Communications
  • Ms. Tonya A. Austin SPHR (Age 50)
    Sr. VP of HR
  • Ms. Deborah Yount
    Chief HR Officer













ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price forecast for 2023?

4 brokerages have issued twelve-month price objectives for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $71.00. On average, they expect the company's stock price to reach $60.17 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2022?

AtriCure's stock was trading at $69.53 at the start of the year. Since then, ATRC stock has decreased by 34.5% and is now trading at $45.56.
View the best growth stocks for 2022 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,320,000 shares, an increase of 9.1% from the October 31st total of 1,210,000 shares. Based on an average trading volume of 303,700 shares, the short-interest ratio is presently 4.3 days. Currently, 2.9% of the shares of the stock are short sold.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Wednesday, November, 3rd. The medical device company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $2.39. The medical device company earned $70.46 million during the quarter, compared to analyst estimates of $68.95 million. AtriCure had a negative trailing twelve-month return on equity of 12.09% and a negative net margin of 17.76%. During the same period last year, the business earned ($0.11) EPS.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of -$1.12--$1.10 for the period, compared to the consensus estimate of -$1.10. The company issued revenue guidance of $328.00 million-$333.00 million, compared to the consensus revenue estimate of $328.61 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.23%), Alliancebernstein L.P. (8.71%), BlackRock Inc. (7.70%), Fred Alger Management LLC (5.00%), First Light Asset Management LLC (3.21%) and Macquarie Group Ltd. (2.93%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $45.56.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.12 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does AtriCure have?

The company employs 875 workers across the globe.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 12/1/2022 by MarketBeat.com Staff